Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Regenerative Medicine Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for HGFAC drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | HGFAC ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View HGFAC Products |
| Gene Delivery | HGFAC Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View HGFAC Products |
| Benchmark Ab | Anti-HGFAC Recombinant Antibody Recombinant positive control. |
View HGFAC Products |
| Validator | HGFAC siRNA Set For knockdown verification. |
View HGFAC Products |
| Related Target A | HGF Direct downstream substrate; cleavage by HGFAC activates HGF/c-MET signaling. |
View HGF Products |
| Related Target B | MET Receptor tyrosine kinase activated by HGF, driving tumor cell motility and survival. |
View MET Products |
| Related Target C | SPINT1 Endogenous inhibitor of HGFAC (HAI-1), critical for off-target and selectivity profiling. |
View SPINT1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Zymogen vs. Active Form Differentiation | Distinct pro-form and activated HGFAC recombinant proteins available with sequence-verified cleavage sites. |
| Serine Protease Subfamily Off-Target Screening | Homolog panel proteins (Factor XIIa, Matriptase, Hepsin) strictly verified by mass spectrometry and high purity (>95%). |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) and sequence-verified positive controls included. |
| False Positives in Cleavage Assays | Validated siRNA sets included for specific target knockdown verification in cell-based assays. |
Live HGFAC R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for HGFAC therapeutics is intensifying, with major players shifting focus from traditional mAbs to selective small-molecule inhibitors and antibody-drug conjugates (ADCs) targeting the tumor microenvironment. HGFAC (Hepatocyte Growth Factor Activator) is a key serine protease responsible for converting single-chain HGF into its active heterodimeric form, which subsequently triggers the c-MET oncogenic pathway. As first-generation c-MET therapies face resistance challenges, the next wave of R&D is targeting HGFAC to shut down the upstream activation cascade selectively in tumor tissues, avoiding systemic toxicities associated with direct c-MET inhibition.
Competitive Modality & Indication Snapshot
Connect market trends to assay needs.
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (mAb) | Biotech Startups, Academic Institutes | Colorectal Cancer, Gastric Cancer | Conformational Binding Assays (Need HEK293-expressed native glycosylation HGFAC) |
| Small Molecule Inhibitor | Oncology-focused Pharma | NSCLC, Hepatocellular Carcinoma | Enzymatic Selectivity Panels (Need high-purity active HGFAC vs. related serine proteases) |
| Peptide Mimetic (HAI-1/2) | Translational Medicine Groups | Metastatic Solid Tumors | Competitive Inhibition Profiling (Need sequence-verified SPINT1/HGFAC recombinant proteins) |